# Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction

> **NCT01962246** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hebei Medical University** · enrollment: 169 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Oxaliplatin; Capecitabine
- **OTHER:** Oxaliplatin; Capecitabine; concurrent radiotherapy

## Key facts

- **NCT ID:** NCT01962246
- **Lead sponsor:** Hebei Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2020-02
- **Final completion:** 2021-08
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01962246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01962246, "Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01962246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*